SEC Form 4 · accession 0001179110-18-009494
ACCELERON PHARMA INC · XLRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert K Zeldin
Officer — EVP & Chief Medical Officer
Period of report
Jul 2, 2018
Accepted (ET)
Jul 5, 2018 · 4:47 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001280600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 2, 2018 | A | 16,903 | $0.00 | A | 16,903 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $47.33 | Jul 2, 2018 | A | 85,511 | A | — | Jul 2, 2028 | Common Stock | 85,511 | 85,511 | D |
Explanation of responses
- F1The shares of common stock underlying this stock option award vest as to 25% of the shares on the first anniversary of June 29, 2018 and the remaining shares vest in equal quarterly installments over the following three years thereafter.